Study of MET protein levels andMETgene copy number in 72 sinonasal intestinal-type adenocarcinomas

Head and Neck - Tập 37 Số 11 - Trang 1563-1568 - 2015
Fabrice Projetti1, Laura Mesturoux1, Béma Coulibaly1, Karine Faucher1, Alain Chaunavel1, Sophie Léobon2, Emilie Gadeaud1, François Caire3, J. Bessede4, François Labrousse1
1Department of Pathology, Dupuytren University Hospital, Limoges, France
2Department of Medical Oncology, Dupuytren University Hospital, Limoges, France.
3Department of Neurosurgery, Dupuytren University Hospital, Limoges, France
4Department of Head and Neck Surgery, Dupuytren University Hospital, Limoges, France.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Turner, 2012, Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data, Head Neck, 34, 877, 10.1002/hed.21830

Barnes, 2005, Pathology and genetics of head and neck tumours

Mills, 2000, Tumors of the upper aerodigestive tract and ear, 455

Choussy, 2008, Adenocarcinoma of ethmoid: a GETTEC retrospective multicenter study of 418 cases, Laryngoscope, 118, 437, 10.1097/MLG.0b013e31815b48e3

Cantu, 2011, Intestinal type adenocarcinoma of the ethmoid sinus in wood and leather workers: a retrospective study of 153 cases, Head Neck, 33, 535, 10.1002/hed.21485

Birchmeier, 2003, Met, metastasis, motility and more, Nat Rev Mol Cell Biol, 4, 915, 10.1038/nrm1261

Sadiq, 2013, MET as a possible target for non-small-cell lung cancer, J Clin Oncol, 31, 1089, 10.1200/JCO.2012.43.9422

De Oliveira, 2009, MET is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality, Anticancer Res, 29, 4807

Di Renzo, 1995, Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer, Clin Cancer Res, 1, 147

Zeng, 2008, c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases, Cancer Lett, 265, 258, 10.1016/j.canlet.2008.02.049

Abou-Bakr, 2013, c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma, Gulf J Oncolog, 1, 28

Breindel, 2013, EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis, Cancer Res, 73, 5053, 10.1158/0008-5472.CAN-12-3775

Jo, 2000, Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells, J Biol Chem, 275, 8806, 10.1074/jbc.275.12.8806

Puri, 2008, Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer, J Carcinog, 7, 9, 10.4103/1477-3163.44372

Tanizaki, 2011, Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification, Br J Cancer, 105, 807, 10.1038/bjc.2011.322

Projetti, 2013, Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas, Hum Pathol, 44, 2116, 10.1016/j.humpath.2013.03.019

Szablewski, 2013, EGFR expression and KRAS and BRAF mutational status in intestinal-type sinonasal adenocarcinoma, Int J Mol Sci, 14, 5170, 10.3390/ijms14035170

Cappuzzo, 2009, Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients, J Clin Oncol, 27, 1667, 10.1200/JCO.2008.19.1635

Park, 2012, High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients, Histol Histopathol, 27, 197

Bendell, 2013, Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer, Clin Colorectal Cancer, 12, 218, 10.1016/j.clcc.2013.04.001

Spigel, 2012, Clin Lung Cancer, 13, 500

Scagliotti, 2012, Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer, Clin Lung Cancer, 13, 391, 10.1016/j.cllc.2012.01.003

Bardelli, 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer, Cancer Discov, 3, 658, 10.1158/2159-8290.CD-12-0558

Inno, 2011, Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?, Clin Colorectal Cancer, 10, 325, 10.1016/j.clcc.2011.03.028

Kishiki, 2014, Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS, Cancer Chemother Pharmacol, 73, 749, 10.1007/s00280-014-2401-4

Sobin, 2010, International Union against Cancer. TNM classification of malignant tumours, 7, 309

Go, 2010, High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer, J Thorac Oncol, 5, 305, 10.1097/JTO.0b013e3181ce3d1d

Varella-Garcia, 2009, EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer, J Clin Pathol, 62, 970, 10.1136/jcp.2009.066548

Franchi, 2009, Epidermal growth factor receptor expression and gene copy number in sinonasal intestinal type adenocarcinoma, Oral Oncol, 45, 835, 10.1016/j.oraloncology.2008.12.005

Carracedo, 2009, FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors, Breast Cancer Res, 11, 402, 10.1186/bcr2239

Janjigian, 2011, MET expression and amplification in patients with localized gastric cancer, Cancer Epidemiol Biomarkers Prev, 20, 1021, 10.1158/1055-9965.EPI-10-1080

Santoro, 2013, Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study, Lancet Oncol, 14, 55, 10.1016/S1470-2045(12)70490-4

García-Inclán, 2012, EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas, Cell Oncol, 35, 443, 10.1007/s13402-012-0103-7

Martin, 2009, An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology, J Clin Pathol, 62, 314, 10.1136/jcp.2008.059592

Kondo, 2013, Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma, Int J Clin Oncol, 18, 207, 10.1007/s10147-011-0361-9

Cappuzzo, 2008, Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients, Br J Cancer, 99, 83, 10.1038/sj.bjc.6604439

Dziadziuszko, 2012, Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer, J Thorac Oncol, 7, 340, 10.1097/JTO.0b013e318240ca0d

Lee, 2012, MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome, Br J Cancer, 107, 325, 10.1038/bjc.2012.237

Lee, 2013, A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma, Anticancer Res, 33, 5179

Migliore, 2008, MicroRNAs impair MET-mediated invasive growth, Cancer Res, 68, 10128, 10.1158/0008-5472.CAN-08-2148

Ivan, 1997, Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells, Oncogene, 14, 2417, 10.1038/sj.onc.1201083

López, 2012, KRAS and BRAF mutations in sinonasal cancer, Oral Oncol, 48, 692, 10.1016/j.oraloncology.2012.02.018

Franchi, 1999, Clinical relevance of the histological classification of sinonasal intestinal-type adenocarcinomas, Hum Pathol, 30, 1140, 10.1016/S0046-8177(99)90029-1

Vivanco Allende, 2013, Intestinal-type sinonasal adenocarcinomas. Immunohistochemical profile of 66 cases, Acta Otorrinolaringol Esp, 64, 115, 10.1016/j.otorri.2012.09.002

Arnold, 2012, Therapy options and long-term results of sinonasal malignancies, Oral Oncol, 48, 1031, 10.1016/j.oraloncology.2012.04.005

Bhayani, 2013, Sinonasal adenocarcinoma: a 16-year experience at a single institution, Head Neck

Vergez, 2012, Endoscopic vs transfacial resection of sinonasal adenocarcinomas, Otolaryngol Head Neck Surg, 146, 848, 10.1177/0194599811434903

Ha, 2013, MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas, Mod Pathol, 26, 1632, 10.1038/modpathol.2013.108

Ke, 2009, Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma, Hepatology, 49, 491, 10.1002/hep.22639